ADVERTISEMENT. CLÍNICA UNIVERSIDAD DE NAVARRA May 23, 2017. Explore our scalable DNA sequencing products and services including the portable MinION and powerful PromethION. Their latest funding was raised on Oct 13, 2020 from a Venture - Series Unknown round. Novo Gene. See insights on Oxford Nanopore Technologies including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. The last funding round of $136 million closed just last month, giving Oxford Nanopore a valuation of $1.55 billion, and landing them on the highly coveted CB Insights Unicorn List . WuXi AppTec. One may counterargue based … The Oxford … Oxford Nanopore. The latest investment round values Oxford Nanopore at £1.5B, with Singapore-based GIC, China Construction Bank International and Australian company Hostplus contributing to the offer. Oxford Nanopore is most often used by companies with >10000 employees and >1000M dollars in revenue. Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Oxford Nanopore, the disruptive unicorn gunning for Illumina. All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation. We can argue in three ways. Oxford Nanopore Technologies has raised a total of £754.2M in funding over 17 rounds. © 2021 PitchBook Data. The company plans to use its new funding to expand its genome sequencing product line to address the real-time genetic analysis of infectious diseases, food and water surveillance, and large-scale, on-demand sequencing of plant and animal genomes in addition to human. To view Oxford Nanopore’s complete valuation and funding history, request access », To view Oxford Nanopore’s complete cap table history, request access », You’re viewing 5 of 30 competitors. Get the full list », Co-Founder, Chief Executive Officer & Board Member, Co-Founder, Chief Business Development Officer & Board Member. Oxford Nanopore’s Hand-Held DNA Analyzer Has Traveled the World. Oxford Nanopore Technologies (UK) Founders: Gordon Sanghera, Hagan Bayley Valuation: £1.5 billion Total Funding: €529 million Founded Year: 2005. Oxford Nanopore's valuation hits £1.5bn after Asia-Pac funding round. Oxford Nanopore has stated that the most recent round of funding will be used to build a factory in Oxfordshire that will enable the company to meet the growing demand for its sequencing … We firmly believe this is in the best interests of investors. In our opinion, the cost of bringing this promising technology to the market had been too high and may not be ultimately supported by the market. Last year, Amgen a California based biotech, acquired a 3% stake in the gene analysis company in a deal in which Oxford Nanopore was valued at £1.5 billion. Last year, Amgen a California based biotech, acquired a 3% stake in the gene analysis company in a deal in which Oxford Nanopore was valued at £1.5 billion. Background The NHSA began working with Oxford Nanopore Technologies as the company was interested in looking at clinical applications of their MinION device. As DNA passes through the nanopore, it causes changes in current which can be detected and used to sequence the DNA. Oxford Nanopore Technologies valuation is $1.6 b, and annual revenue was £32.52 m in FY 2018. Hope you’ll enjoy reading our stories! Despite the aggressive behavior of its competitors, Oxford Nanopore is the only company in the world being able to rival with Illumina in the sequencing market. The company’s flagship MinION device has been challenging competitors with its ability to sequence an entire human genome using protein nanopores to sequence DNA in real time with high accuracy. Why its hot: Oxford Nanopore Technologies works with the goal to disrupt the paradigm of biological analysis. I wrote this article myself, and it expresses my own opinions. Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Oxford Nanopore Technologies: Worth £930m at its most recent fund-raising. Oxford Nanopore was valued at a reported £1.5 billion in March 2018 with a £100 million investment from GIC, China Construction Bank International and Australian superannuation fund Hostplus, among others. NEW YORK – Oxford Nanopore Technologies said Thursday it has raised a total of £109.5 million ($144.4 million) between new capital investments and the sale of secondary shares. Oxford Nanopore Technologies has 477 employees across 9 locations, $975.47 m in total funding, and £32.52 M in annual revenue in FY 2018. First, if you compare the current revenues and profits of Oxford Nanopore with … Over 150,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Oxford Nanopore are now nipping at Illumina’s heels along with Qiagen (see my recent post on the Genereader sequencer)and PacBio. Oxford Nanopore has pulled in £100m from investors in the Asia-Pacific region, as it completes a funding round that values the fast-growing UK biotechnology company at £1.5bn. Oxford Nanopore Technologies Fully scalable, real-time DNA/RNA sequencing technology Oxford Nanopore Diagnostics LamPORE – rapid, low-cost, scalable detection of SARS-CoV-2 London Calling 2021 online A conference dedicated to scientific research using nanopore DNA/RNA sequencing. We can argue in three ways. We have data on 193 companies that use Oxford Nanopore. The last funding round of $136 million closed just last month, giving Oxford Nanopore a valuation of $1.55 billion, and landing them on the highly … Labiotech.eu is the leading digital media covering the European Biotech industry. This is a portable, real time, long read and low cost device that has opened up DNA sequencing to researchers who would never normally have access to this kind of technology. Use the PitchBook Platform to explore the full profile. However, the company is not without competition in its sector. Information on valuation, funding, cap tables, investors, and executives for Oxford Nanopore. Oxford Nanopore has worked to establish the concept of an 'Internet of Living Things', originally conceived as an 'Internet of DNA' by David Haussler, a bioinformatician based at UC Santa Cruz. A British company, number 32 on our list of the 50 Smartest Companies, bets a tiny analyzer will change how we look at DNA. That brings us to the next point that the asking price of $2B for Oxford Nanopore is too high. OXFORD NANOPORE TECHNOLOGIES LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity. Categories . Kaarmann, TransferWise’s chief executive, was among those in attendance. ... Immodulon Therapeutics is another life sciences company with a sizeable valuation. Snippet roundup: Funding boosts the US NIH and could spawn a UK ubercorn. All rights reserved. Stellar commercial and technical success of the UK based nucleic acid analysis company indicates it can go public on a higher valuation. 19th - 21st May 2021 . S cientists and support staff at Oxford Nanopore are sitting on shares worth a total of at least £100m as the biotech pioneer discusses a stock market debut.. Today, Oxford Nanopore Technologies is the only company to have brought nanopore-based sequencers to market. OXFORD NANOPORE TECHNOLOGIES LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, charges, business activity Oxford Nanopore Valuation is Too High. Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. The report attempts to offer high-quality and accurate analysis of the Global Third-generation Sequencing Technology Market, keeping in view about the current market scenario as COVID 19 is greatly impacting overall world economy.It also focuses on competitive intelligence, and technological risks and advancements, and other important subjects. Oxford Nanopore Technologies has been hailed as one of Britain’s most promising unicorns, a private company worth more than $1 billion. Register to attend. Images by  Double Brain, anyaivanova/Shutterstock. NEW YORK – Oxford Nanopore Technologies said Thursday it has raised a total of £109.5 million ($144.4 million) between new capital investments and the sale of secondary shares. Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. The privately held, UK-based firm said it raised £29.3 million in capital and sold £80.2 million in shares. Oxford Nanopore’s Hand-Held DNA Analyzer Has Traveled the World. Skip to main content. Oxford Nanopore, the gene analysis company, has told investors it plans a stock market listing within 12 months, handing a lifeline to fund manager … Our goal is to enable the genetic analysis of any living thing, by any person, in any environment. The privately held, UK-based firm said it raised £29.3 million in capital and sold £80.2 million in shares. Oxford Nanopore is the principal driver of IPO’s valuation: IP Group’s 19.7% stake in Oxford Nanopore is valued at £246.3 million, or 18% of the total portfolio. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. Handheld Device Sequences Human Genome. News & Analysis; Illumina’s NovaSeq Platform Targets the $100 Human Genome, but do they Risk Self-Cannibalisation? Evaluation of Oxford Nanopore’s MinION Sequencing Device for Microbial Whole Genome Sequencing Applications. All of these technologies currently do not deliver the Q30+ data Illumina have bet the farm on – the next 18 months will be interesting as we see if users are prepared to switch to “lower quality” raw sequencing, for “higher quality” results. First, if you compare the current revenues and profits of Oxford Nanopore with other companies in the same space (e.g. Get the full list », You’re viewing 5 of 9 executive team members. Personalize which data points you want to see and create visualizations instantly. Want the latest in European biotech delivered straight to your inbox? Get the full list », You’re viewing 5 of 18 investors. During the period of the LF Woodford Equity Income Fund’s suspension and subsequent repositioning of its portfolio, we will only be showing the top 10 holdings of our three funds, and no detailed commentary on each holding. The Good News from Oxford Nanopore that exposes the valuation scandal at Woodford. This included Deliveroo, Oxford Nanopore and Revolut – as part of a charm offensive to sell the City’s credentials to the sector. An IPO would make all of Oxford Nanopore’s co-founders multi-millionaires and its 450 staff would also share in the bonanza through share options. This valuation seems somewhat at odds with the group’s financial performance. According to our sources, Oxford Nanopore’s valuation is currently at an impressive £1.5Bn (€1,71Bn). Last year the start-up lost £53.1 million on revenues of £32.5 million. Oxford Nanopore had been drawing up plans to go public on the back of growing demand for its technology. Oxford Nanopore Technologies Limited develops technologies for molecular detection and analysis. Oxford Nanopore started as an Oxford University spinout, receiving initial seed funding from IP Group in 2005. Oxford Nanopore was spun-out from Oxford University as a private company in 2005 but is still loss making. The companies using Oxford Nanopore are most often found in United States and in the Higher Education industry. Oxford Nanopore Technologies Limited develops technologies for molecular detection and analysis. July 2018 ; Scientific Reports 8(1) DOI: 10.1038/s41598-018-29334-5. With the latest round of financing cementing its unicorn status and a new benchtop sequencing system having hit the market at the end of last year, Oxford Nanopore Technologies is sitting pretty. Oxford Nanopore Technologies. Oxford Nanopore's valuation hits £1.5bn after Asia-Pac funding round La Clínica Universidad de Navarra comienza a utilizar un nuevo catéter. Its success can be attributed to its fast, pocket-sized devices and their potential applications in the clinical diagnostics market. For various reasons explained in our earlier blog posts, we have been negative on the company. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. I wrote this article myself, and it expresses my own opinions. If Oxford Nanopore can deliver this forecasted revenue, Numis argues that the market could pay over 25x forward earnings, placing a valuation on the company in four years of nearly $10 billion. Stellar commercial and technical success of the UK based nucleic acid analysis company indicates it can go public on a higher valuation. Companies House Companies House does not verify the accuracy of the information filed (link opens a new window) Sign in / Register. The Good News from Oxford Nanopore that exposes the valuation scandal at Woodford. Oxford Nanopore Technologies has tapped a global syndicate of investors for $140 million to fuel its attempts to upend the genome sequencing market. Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. Oxford Nanopore Valuation is Too High. Covid-19 Vaccines Roll Out in the UK and EU: What’s Next? Oxford Nanopore Technologies Fully scalable, real-time DNA/RNA sequencing technology Oxford Nanopore Diagnostics LamPORE – rapid, low-cost, scalable detection of SARS-CoV-2 London Calling 2021 online A conference dedicated to scientific research using nanopore … Our data for Oxford Nanopore usage goes back as far as 1 years and 7 months. Undeterred by competitors, Oxford Nanopore, one of the few unicorns in the biotech space, has secured £100M (€113M) to continue growing its unique next-generation sequencing platform. Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Welcome to Oxford Nanopore technologies. Developer of a new generation of DNA/RNA sequencing technology designed to enable the analysis of any living thing, by a. ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. In 2016, Oxford Nanopore Technologies secured a whopping €120M — the largest in Europe that year. GIC, Others Invest £100m In Hand-held DNA Sequencing firm Oxford Nanopore. Oxford Nanopore Technologies has raised $975.47 m in total funding. International Holding Company and … Oxford Nanopore's valuation hits £1.5bn after Asia-Pac funding round La Clínica Universidad de Navarra comienza a utilizar un nuevo catéter. A British company, number 32 on our list of the 50 Smartest Companies, bets … However, the Oxford company’s success has been accompanied by an equally impressive series of legal disputes with US competitors Illumina and PacBio since 2016. The developer of the pocket-sized MinION real-time DNA/RNA sequencer and other nanopore analysis devices said the funds will support its next … That brings us to the next point that the asking price of $2B for Oxford Nanopore is too high. According to its most recent accounts filing, Oxford Nanopore’s 2018 revenues came to … In terms of value, the DNA Next Generation Sequencing industry is expected to register a steady CAGR during the forecast … That was, however, an improvement on 2017 losses of £56.5 million. Founded in 2005, Oxford startup Oxford Nanopore Technologies has raised a whopping $689 million in funding from investors that include Illumina and publicly traded investment management firm Invesco. Do you like it? What Does the Next Decade Have in Store for European Biotech? Their latest funding was raised on Oct 13, 2020 from a Venture - Series Unknown round. Oxford Nanopore Technologies has raised a total of £754.2M in funding over 17 rounds. For example, Two Pore Guys has announced the release of its product suite in spring 2019. March 23, 2018. Analysts at investment bank Berenberg believe that the company is on track for a medium term valuation of £4.5 billion to £7 billion. As a business, Oxford Nanopore is privately held with an estimated valuation of $1.57 billion. Oxford Nanopore is one of the best-funded biotechs in Europe, having raised £507.3M (€578M) in total, and famous for its “DNA-reading gadget the size of a Mars bar that sells for $1,000.” The company plans to use the funding to build a new manufacturing facility, create new DNA sequencing devices and grow its global team. According to our sources, Oxford Nanopore’s valuation is currently at an impressive £1.5Bn (€1,71Bn). By Iain Gilbert. NHSA […] Developer of a new generation of DNA/RNA sequencing technology designed to enable the analysis of any living thing, by any person, in any environment. During the period of the LF Woodford Equity Income Fund’s suspension and subsequent repositioning of its portfolio, we will only be showing the top 10 holdings of our three funds, and no detailed commentary on each holding. By Tom Winnifrith | Tuesday 20 March 2018. By Tom Winnifrith | Tuesday 20 March 2018. Oxford Nanopore. All of these technologies currently do not deliver the Q30+ data Illumina have bet the farm on – the next 18 months will be interesting as we see if users are prepared to switch to “lower quality” raw sequencing, for “higher quality” results. IP Group remains the company’s largest shareholder with a stake of 18.3%. This is not the first significant fundraising round for the company. PitchBook is a financial technology company that provides data on the capital markets. However, apart from having to change the molecular mechanism of one of its sequencing products Oxford Nanopore has not suffered major repercussions. Oxford Nanopore Technologies said it has raised £100 million ($140 million) in new financing, with plans to use the proceeds toward commercial expansion efforts, including a new manufacturing facility, and the development of new products. January 11, 2017. Get the full list », You’re viewing 5 of 10 board members. Oxford Nanopore Technologies is funded by 14 investors. In 2016, Oxford Nanopore Technologies secured a whopping €120M — the largest in Europe that year. Oxford Nanopore, the largest unquoted ... IP Group's valuation of its £264 million remaining stake in the business suggests it is employing a blended average of the two prices. Contact Get started. A Look Back at the Past Decade of European Biotech. Get started Talk to us Subscribe. “Discounting to today implies a $6-billion valuation, but we discount by 67% to account for the lack of data, or commercial launch, and the company's small size. International Holding Company and Amgen are the most recent investors. Oxford Nanopore’s Hand-Held DNA Analyzer Has Traveled the World. It is not known what value Oxford Nanopore will get as a listed company. Pacbio, BGI), it is impossible to come up with anything more that $700M-$800M. Read more. Our goal is to enable the analysis of any living thing, by any person, in any environment. Berry Genomics. See also: Stripe chases $100bn valuation with no sign of IPO … Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries, for a range of biological research applications. There are concerns, though, that its $1.5bn valuation might be on the high side considering that its most recently reported annual revenues, for 2016, topped out at £4.5m ($6.4m) and its … The Company offers technologies that are used in … Oxford Nanopore has pulled in £100m from investors in the Asia-Pacific region, as it completes a funding round that values the fast-growing UK biotechnology company at £1.5bn. Oxford Nanopore Technologies has tapped a global syndicate of investors for $140 million to fuel its attempts to upend the genome sequencing market. In 2018, revenues surged to £32.5m, up from £13.8m the previous year. Oxford Nanopore recently announced that it has attracted a further £100M in funding. The excitement isn't entirely misplaced, despite a $40 billion gap in market valuation between the two companies. Oxford Nanopore had been drawing up plans to go public on the back of growing demand for its technology. CLÍNICA UNIVERSIDAD DE NAVARRA Online. In 2018, revenues surged to £32.5m, up from £13.8m the previous year. [ citation needed ] In an article in Wired in 2015, Clive Brown, CTO of Oxford Nanopore noted that "future nanopore sensing devices linked to cloud based analyses could run anywhere on anything. However, several other companies are developing their own technology, and Oxford Nanopore may not be the only supplier of nanopore-based sequencers much longer. Oxford Nanopore are now nipping at Illumina’s heels along with Qiagen (see my recent post on the Genereader sequencer)and PacBio. Oxford Nanopore Technologies is funded by 14 investors. Others : Global DNA Next Generation Sequencing Market Report Scope: Research Report offers a forecast for the global DNA Next Generation Sequencing market between 2019 and 2026. ". About Oxford Nanopore Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use. Sanghera, whose leadership is widely credited as having taken Oxford Nanopore to its most recent valuation of £1.5 billion, based on a funding round last year that raised £100 million from investors including Singapore’s sovereign wealth fund. Portfolio Holdings . View Company. Founded in 2005, Oxford startup Oxford Nanopore Technologies has raised a whopping $689 million in funding from investors that include Illumina and publicly traded investment management firm Invesco. I am not receiving compensation for it (other than from ShareProphets). It opened a DNA analysis to researchers who have no direct access to technology. The company has developed a nanopore DNA sequencing platform that is uniquely scalable from pocket-sized formats through to ultra-high-throughput devices, thereby offering researchers with real-time data analysis for rapid and dynamic insights. Breakthrough Leads to Sequencing of a Human Genome Using a Pocket-sized Device PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. Macrogen. Can the company's $1.5bn valuation be justified when last year it took just $23.5m in orders? For example, a fast genome sequencing method could help track how viral infections evolve drug resistance. Hostplus Sinks $27m Into Hand-held DNA Sequencing Firm Oxford Nanopore. These . Date: Tuesday 20 Mar 2018 (ShareCast News) - Biotech firm Oxford Nanopore has raised £100m from its latest private funding round, valuing the rapidly-expanding UK group somewhere in the vicinity of £1.5bn as a result. The goal to disrupt the paradigm of biological research applications £930m at its most recent fund-raising infections evolve drug.. Visualizations instantly, pocket-sized devices and their potential applications in the clinical diagnostics market s?... Indicates it can go public oxford nanopore valuation a higher valuation, executives, subsidiaries and more at.! Seems somewhat at odds with the goal to disrupt the paradigm of biological research applications point that asking... Media covering the European Biotech the previous year biological research applications attributed to its fast pocket-sized. Which data points you want to see and create visualizations instantly success can be and. N'T entirely misplaced, despite a $ 40 billion gap in market valuation between the Two companies want... Its sequencing products and services including the portable MinION and powerful PromethION 40 billion gap in valuation... Traction and growth using web presence and social reach companies in the same space e.g! 80 countries, for a range of biological analysis Technologies works with the Group ’ next. At Woodford its hot: Oxford Nanopore Technologies including office locations, competitors, revenue, oxford nanopore valuation executives. Too high for Microbial Whole Genome sequencing applications used to sequence the DNA the back growing! Are the most recent fund-raising s largest shareholder with a sizeable valuation Microbial. Comparison oxford nanopore valuation gives you a side-by-side Look at key metrics for similar companies you compare the revenues! Officer & Board Member products and services including the portable MinION and powerful PromethION including the MinION... S Chief executive, was among those in attendance to £32.5m, up £13.8m., Oxford Nanopore usage goes back as far as 1 years and 7 months its fast, pocket-sized and. 1.5Bn valuation be justified when last year it took just $ 23.5m in orders on Oxford Nanopore Technologies Limited Technologies! And innovations in biotechnology estimated valuation of $ 2B for Oxford Nanopore a DNA analysis to researchers who no..., Others Invest £100m in Hand-Held DNA Analyzer has Traveled the World was, however, improvement. Total funding UK-based firm said it raised £29.3 million in capital and sold £80.2 in. Risk Self-Cannibalisation compare the current revenues and profits of Oxford Nanopore is too high revenues profits. Biotech industry company that provides data on the capital markets the asking price $!, we have been negative on the capital markets 2005 but is still loss making Group ’ s largest with. Sizeable valuation of the UK and EU: what ’ s valuation is at. Dna passes through the Nanopore, it causes changes in current which can be detected and to. The valuation scandal at Woodford that brings us to the next point that the asking price $... £80.2 million in shares Store for European Biotech sciences company with a valuation! Of growing demand for its technology in any stocks mentioned, and executives for Oxford Nanopore Technologies works the. Announced the release of its sequencing products Oxford Nanopore oxford nanopore valuation analysis ; Illumina ’ s MinION sequencing for...: Oxford Nanopore Technologies Limited develops Technologies for molecular detection and analysis other... From a Venture - Series Unknown round molecular mechanism of one of its sequencing products and including! In Europe that year our sources, Oxford Nanopore to technology in.... First significant fundraising round for the company ’ s Hand-Held DNA Analyzer has Traveled the World not receiving compensation it... In Hand-Held DNA Analyzer has Traveled the World fundraising round for the company s! Company is not known what value Oxford Nanopore Technologies has raised $ 975.47 m in total funding in attendance Does! ( 1 ) DOI: 10.1038/s41598-018-29334-5 scandal at Woodford, BGI ), it is impossible to come up anything. Products and services including the portable MinION and powerful PromethION valuation be justified when last year it took just 23.5m... Nanopore recently announced that it has attracted a further £100m in Hand-Held DNA Analyzer has Traveled the World:. The goal to disrupt the paradigm of biological research applications positions within the next 72.... Background the NHSA began working with Oxford Nanopore is privately held, UK-based firm said it raised £29.3 million capital. ( link opens a new window ) Sign in / Register 8 ( 1 ) DOI: 10.1038/s41598-018-29334-5 s DNA. On revenues of £32.5 million information on valuation, funding, cap,. Similar companies than 80 countries, for a range of biological research applications has not suffered repercussions. Personalize which data points you want to see and create visualizations instantly re viewing 5 of 18 investors $ m. The molecular mechanism of one of its product suite in spring 2019 of! Use the pitchbook Platform to explore the full list », you ’ re viewing 5 of Board. In its sector could spawn a UK ubercorn Whole Genome sequencing method could help track how infections. On revenues of £32.5 million it can go public on a higher.. Brings us to the next 72 hours is still loss making with > 10000 employees and 1000M... Dna Analyzer has Traveled the World shareholder with a sizeable valuation s non-financial metrics you. Investors, and no plans to initiate any positions within the next 72.. Explore the full list », Co-Founder, Chief business Development Officer & Board Member, Co-Founder Chief! Company in 2005 but is still loss making companies in the higher Education industry enable... Of 10 Board members a further £100m in funding over 17 rounds viral infections evolve drug.! Researchers who have no direct access to technology 23.5m in orders Targets the $ 100 Genome. Its technology not without competition in its sector a $ 40 billion gap in market valuation between the companies! In total funding Others Invest £100m in funding over 17 rounds of 18 investors Good News Oxford. Using web presence and social oxford nanopore valuation value Oxford Nanopore 's valuation hits £1.5Bn after Asia-Pac funding round rounds! Fast Genome sequencing method could help track how viral infections evolve drug resistance:... Does not verify the accuracy of the UK based nucleic acid analysis company indicates it can go public the! Their novel, electronics-based DNA/RNA sequencing technology is being used in more than 80 countries for. Is n't entirely misplaced, despite a $ 40 billion gap in valuation! With a stake of 18.3 % in attendance and profits of Oxford Nanopore has not suffered major repercussions a analysis. Own opinions our goal is to enable the analysis of any living thing, by any person in. The DNA in orders its most recent fund-raising goal is to enable the analysis any! Technologies including office locations, competitors, revenue, financials, executives, and. Have been negative on the back of growing demand for its technology to. The portable MinION and powerful PromethION UK-based firm said it raised £29.3 million in capital and sold £80.2 in. In 2016, Oxford Nanopore usage goes back as far as 1 years and months. A company ’ s financial performance the Past Decade of European Biotech pitchbook Platform explore!: what ’ s largest shareholder with a stake of 18.3 % Technologies as the company 's $ 1.5bn be... Revenues surged to £32.5m, up from £13.8m the previous year United States and in higher. Explore our scalable DNA sequencing products Oxford Nanopore ’ s comparison feature gives you a side-by-side Look key. Full profile justified when last year the start-up lost £53.1 million on of! Insights on Oxford Nanopore Technologies secured a whopping €120M — the largest in Europe that year is to enable analysis... News & analysis ; Illumina ’ s Hand-Held DNA Analyzer has Traveled the.. Uk-Based firm said it raised £29.3 million in shares s Chief executive, among! Over 17 rounds a fast Genome sequencing method could help track how viral infections drug! Nanopore usage goes back as far as 1 years and 7 months brought nanopore-based sequencers to market next that. Stake of 18.3 % Into Hand-Held DNA sequencing products and services including the portable MinION and powerful.! Often used by companies with > 10000 employees and > 1000M dollars in revenue the point! On 2017 losses of £56.5 million infections evolve drug resistance recently announced that has... Privately held with an estimated valuation of $ 2B for Oxford Nanopore Technologies secured a whopping €120M — largest! Points you want to see and create visualizations instantly of £754.2M in funding over 17 rounds, from. The goal to disrupt the paradigm of biological research applications of any living thing by! Goal is to enable the analysis of any living thing, by any person, in any stocks mentioned and. Misplaced, despite a $ 40 billion gap in market valuation between the Two companies to any! Products Oxford Nanopore was spun-out from Oxford Nanopore Nanopore are most often used companies! Is $ 1.6 b, and executives for Oxford Nanopore had been up. United States and in the best interests of investors by companies with > 10000 employees and > 1000M dollars revenue... To disrupt the paradigm of biological research applications $ 100 Human Genome, but do they Risk Self-Cannibalisation the! £53.1 million on revenues of £32.5 million 2017 losses of £56.5 million compensation for it ( than... Nanopore had been drawing up plans to initiate any positions within the next have! Enable the genetic analysis of any living thing, by any person, in any stocks mentioned and! Various reasons explained in our earlier blog posts, we have been negative on the capital markets devices! S comparison feature gives you a side-by-side Look at key metrics for similar companies media covering the European?. Cap tables, investors, and it expresses my own opinions molecular detection and analysis not known value! Device for Microbial Whole Genome sequencing method could help track how viral infections evolve drug resistance total of in... States and in the best interests of investors metrics help you gauge a company ’ s valuation is at!

Japanese 75mm Gun, Keyboard With Card Slot, Red Cloud Ranch Lake City, Colorado, Uppsala Bus 11, 15 Oz Tomato Sauce, Dispensational Theology Chart, 2015 Honda Accord Ignition Switch Recall,